SABCS24 Day 2 Highlights from Oncology Brothers

Oncology Brothers posted on X:

“SABCS24 Day 2 Highlights

1. EMBER3: Oral SERD in HR+
2. OlympiA: PARPi in gBRCA
3. Surgery in gBRCA.”

“EMBER3: Ph III, Imlunestrant +/- Abemaciclib in HR+ advanced BC

– Imlunestrant alone for mESR1(mPFS: 5.5mos vs 3.8mos)
– Combo mPFS with all comers (9.4mos vs 5.5mos), regardless of CDK4/6 exposure
– If co-PIK3CA, Capi or this combo?.”

Quoting Paolo Tarantino’s post below:

“The new Halgorithm for treating HR+/HER2- metastatic breast cancer.”

“OlympiA: Update, Ph III, Olaparib in mBRCA HER2 -ve, EBC, high-risk s/p local Rx + neo or adj chemo, at 6 years:

– iDFS by 9.4% & DDFS by 7.8%
– mOS by 4.4% (87.5% vs 83.2%), HR: 0.72
– Remains the current SoC in this pt population.”

Quoting Eleonora Teplinsky’s post below:

“OlympiA Update:

At a median follow-up of 6.1 years: 6-year IDFS rate showed a 9.4% absolute benefit for olaparib with a hazard ratio of 0.65.
Also observed in DDFS (7.8% absolute benefit) and OS (4.4% absolute benefit).
Consistent across all subgroups.
Pregnancy data were similar between the two arms.
Low rate of 0.4% MDS/AML in the olaparib arm compared to 0.7% in the placebo arm.”

” Risk Reduction surgery in young BRCA carriers: <40 year old with Stage I-III breast cancer undergoing Risk-reducing mastectomy (RRM) and salpingo-oophorectomy (RRSO)

– RRM and/or RRSO associated with better OS
– RRSO benefit more pronounced with BRCA1.”

Quoting Erika Hamilton’s post below:

“Matteo Lambertini presents data around risk-reducing surgery in young BRCA carriers with a prior breast cancer.

Both mastectomies and oophorectomy were associated with

• OS
• DFS
• BCFI

Risk-reducing mastectomy (RRM) irrespective of which BRCA gene alteration, risk-reducing salpingo-oophorectomy (RRSO) benefit higher among BRCA1.”

Drs. Rohit Gosain and Rahul Gosain (aka Oncology Brothers),  are medical oncologists/hematologists. Through their social media platforms like X/Twitter, they actively engage with their audience. With their own YouTube channel and podcast, they provide accessible resources for cancer patients and their families. Additionally, their participation in live conferences ensures that cancer patients receive the best care closer to home, reflecting their commitment to advancing oncology and improving patient outcomes through education and outreach.

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.

Eleonora Teplinsky is a medical oncologist specializing in breast and gynecologic oncology. She is the head of breast and gynecological medical oncology at Valley-Mount Sinai Comprehensive Cancer Care in Paramus, New Jersey, and a clinical assistant professor of medicine at the Icahn School of Medicine at Mount Sinai in New York. Her clinical and research interests focus on young women with breast cancer, survivorship, exercise oncology, and the use of social media in oncology. She is passionate about oncology education and advocacy on social media and is the host of the INTERLUDE Podcast, where she shares the stories and experiences of those who have been affected by cancer. Dr. Teplinsky is the co-lead of the The Collaboration for Outcomes using Social Media in Oncology (COSMO) – a social media lab working to provide a venue for social media research in oncology.

Erika Hamilton is a medical oncologist and the Director of Breast Cancer Program at Sarah Cannon Research Institute (USA). Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee. She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.